Cardiff Oncology, Inc. (CRDF): Cash & Equivalents
$17.47M
As of 2025-12-31
$9.20M
As of 2026-06-30
+2.2%
3-year compound annual growth
-33.2%
5-year compound annual growth
-12.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.47M | -66.1% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $51.47M | +137.7% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $21.66M | +32.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $16.35M | +36.9% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $11.94M | -90.9% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $130.98M | n/m | 2022-02-24, Balance as of period end |
| 2019-12-31 | $10.20M | -11.0% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $11.45M | +39.2% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $8.23M | -40.9% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $13.92M | -79.4% | 2018-02-26, Balance as of period end |
| 2015-12-31 | $67.49M | +147.3% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $27.29M | +5.6% | 2017-03-15, Balance as of period end |
| 2013-12-31 | $25.84M | +138.8% | 2016-03-10, Balance as of period end |
| 2012-12-31 | $10.82M | n/m | 2015-03-12, Balance as of period end |
| 2011-12-31 | $700.4K | n/m | 2014-03-17, Balance as of period end |
| 2010-12-31 | $58.7K | n/a | 2014-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
| Pluri Inc. (PLUR) | 2026-06-30 | $3.53M | -40.1% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $124.22M | -18.6% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
Compare CRDF, IMA, PROK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗